SYDNEY, March 29, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology drug development company, is pleased to announce commencement of an international phase II clinical trial of its lead program, GDC-0084. Key Points First site,...
from PR Newswire: //https://ift.tt/2Gjtenq
No comments:
Post a Comment